Work

Dual biologic therapy in patient with refractory ulcerative colitis and comorbidities: A case report

Year: 2025

Type: article

Abstract: BACKGROUND: Despite advances in the treatment of ulcerative colitis (UC), some patients remain refractory to the currently available treatments. Dual biologic therapy (DBT) has emerged as a promising strategy for these patients. CASE SUMMARY: A patient with extensive UC presented with steroid dependence and contraindications (past medical history included breast cancer and previous myocardial infarction) to treatment with tumor necrosis factor and Janus kinase inhibitors. DBT of α4β7 integrin antagonist (vedolizumab) and interleukin 23p19 inhibitor (mirikizumab) resulted in a sustained clinical and biochemical remission. No adverse events were recorded during the follow-up. CONCLUSION: This case highlighted the challenge of managing refractory UC, especially in frail patients.

Source: World Journal of Gastroenterology

DOI: 10.3748/wjg.v31.i47.113381

Authors: Andreia C Guimarães, Rocio Ferreiro-Iglesias, Cristina Calviño-Suarez, Iria Baston-Rey, Manuel Barreiro-de Acosta

Institutions: Unidade Local de Saúde de Braga, Complejo Hospitalario Universitario de Santiago, Instituto de Investigación Sanitaria de Santiago

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W7116048034